118 related articles for article (PubMed ID: 37308558)
1. Optimized collaboration of the first and third signals endows robust activity to T cells within the immunocompetent tumor microenvironment.
Wei J; Lin X; Han W
Cell Mol Immunol; 2023 Nov; 20(11):1393-1394. PubMed ID: 37308558
[No Abstract] [Full Text] [Related]
2. CD47 in the tumor microenvironment limits cooperation between antitumor T-cell immunity and radiotherapy.
Soto-Pantoja DR; Terabe M; Ghosh A; Ridnour LA; DeGraff WG; Wink DA; Berzofsky JA; Roberts DD
Cancer Res; 2014 Dec; 74(23):6771-83. PubMed ID: 25297630
[TBL] [Abstract][Full Text] [Related]
3. Lenvatinib plus anti-PD-1 antibody combination treatment activates CD8+ T cells through reduction of tumor-associated macrophage and activation of the interferon pathway.
Kato Y; Tabata K; Kimura T; Yachie-Kinoshita A; Ozawa Y; Yamada K; Ito J; Tachino S; Hori Y; Matsuki M; Matsuoka Y; Ghosh S; Kitano H; Nomoto K; Matsui J; Funahashi Y
PLoS One; 2019; 14(2):e0212513. PubMed ID: 30811474
[TBL] [Abstract][Full Text] [Related]
4. Anti-PD-1 Induces M1 Polarization in the Glioma Microenvironment and Exerts Therapeutic Efficacy in the Absence of CD8 Cytotoxic T Cells.
Rao G; Latha K; Ott M; Sabbagh A; Marisetty A; Ling X; Zamler D; Doucette TA; Yang Y; Kong LY; Wei J; Fuller GN; Benavides F; Sonabend AM; Long J; Li S; Curran M; Heimberger AB
Clin Cancer Res; 2020 Sep; 26(17):4699-4712. PubMed ID: 32554515
[TBL] [Abstract][Full Text] [Related]
5. Established fibrous peritoneal metastasis in an immunocompetent mouse model similar to clinical immune microenvironment of gastric cancer.
Fujimori D; Kinoshita J; Yamaguchi T; Nakamura Y; Gunjigake K; Ohama T; Sato K; Yamamoto M; Tsukamoto T; Nomura S; Ohta T; Fushida S
BMC Cancer; 2020 Oct; 20(1):1014. PubMed ID: 33081727
[TBL] [Abstract][Full Text] [Related]
6. Expression of B7-H2 on CD8
Cao Y; Cao T; Zhao W; He F; Lu Y; Zhang G; Hu H; Wang Z
Int Immunopharmacol; 2018 Mar; 56():128-134. PubMed ID: 29414642
[TBL] [Abstract][Full Text] [Related]
7. Tumor endothelial cell-induced CD8
Sakano Y; Noda T; Kobayashi S; Sasaki K; Iwagami Y; Yamada D; Tomimaru Y; Akita H; Gotoh K; Takahashi H; Asaoka T; Tanemura M; Wada H; Doki Y; Eguchi H
Cancer Sci; 2022 May; 113(5):1625-1638. PubMed ID: 35289033
[TBL] [Abstract][Full Text] [Related]
8. Inhibiting the CD8
Chen HY; Xu L; Li LF; Liu XX; Gao JX; Bai YR
Sci Rep; 2018 Aug; 8(1):11934. PubMed ID: 30093664
[TBL] [Abstract][Full Text] [Related]
9. Serial low doses of sorafenib enhance therapeutic efficacy of adoptive T cell therapy in a murine model by improving tumor microenvironment.
Chuang HY; Chang YF; Liu RS; Hwang JJ
PLoS One; 2014; 9(10):e109992. PubMed ID: 25333973
[TBL] [Abstract][Full Text] [Related]
10. Cytotoxic CD8
Iwahori K
Adv Exp Med Biol; 2020; 1224():53-62. PubMed ID: 32036604
[TBL] [Abstract][Full Text] [Related]
11. Ablative Tumor Radiation Can Change the Tumor Immune Cell Microenvironment to Induce Durable Complete Remissions.
Filatenkov A; Baker J; Mueller AM; Kenkel J; Ahn GO; Dutt S; Zhang N; Kohrt H; Jensen K; Dejbakhsh-Jones S; Shizuru JA; Negrin RN; Engleman EG; Strober S
Clin Cancer Res; 2015 Aug; 21(16):3727-39. PubMed ID: 25869387
[TBL] [Abstract][Full Text] [Related]
12. Transcription factor RUNX3 promotes CD8
Song Q; Shang J; Zhang C; Chen J; Zhang L; Wu X
J Cell Biochem; 2020 Jun; 121(5-6):3208-3220. PubMed ID: 31898342
[TBL] [Abstract][Full Text] [Related]
13. Endogenous Glucocorticoid Signaling Regulates CD8
Acharya N; Madi A; Zhang H; Klapholz M; Escobar G; Dulberg S; Christian E; Ferreira M; Dixon KO; Fell G; Tooley K; Mangani D; Xia J; Singer M; Bosenberg M; Neuberg D; Rozenblatt-Rosen O; Regev A; Kuchroo VK; Anderson AC
Immunity; 2020 Sep; 53(3):658-671.e6. PubMed ID: 32937153
[TBL] [Abstract][Full Text] [Related]
14. Stromal PD-L1-Positive Regulatory T cells and PD-1-Positive CD8-Positive T cells Define the ResponseĀ of Different Subsets of Non-Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy.
Wu SP; Liao RQ; Tu HY; Wang WJ; Dong ZY; Huang SM; Guo WB; Gou LY; Sun HW; Zhang Q; Xie Z; Yan LX; Su J; Yang JJ; Zhong WZ; Zhang XC; Wu YL
J Thorac Oncol; 2018 Apr; 13(4):521-532. PubMed ID: 29269008
[TBL] [Abstract][Full Text] [Related]
15. C4b-binding protein Ī±-chain enhances antitumor immunity by facilitating the accumulation of tumor-infiltrating lymphocytes in the tumor microenvironment in pancreatic cancer.
Sasaki K; Takano S; Tomizawa S; Miyahara Y; Furukawa K; Takayashiki T; Kuboki S; Takada M; Ohtsuka M
J Exp Clin Cancer Res; 2021 Jun; 40(1):212. PubMed ID: 34167573
[TBL] [Abstract][Full Text] [Related]
16. Recombinant
Deng W; Lira V; Hudson TE; Lemmens EE; Hanson WG; Flores R; Barajas G; Katibah GE; Desbien AL; Lauer P; Leong ML; Portnoy DA; Dubensky TW
Proc Natl Acad Sci U S A; 2018 Aug; 115(32):8179-8184. PubMed ID: 30038013
[TBL] [Abstract][Full Text] [Related]
17. Type 17 immunity promotes the exhaustion of CD8
Kim BS; Kuen DS; Koh CH; Kim HD; Chang SH; Kim S; Jeon YK; Park YJ; Choi G; Kim J; Kang KW; Kim HY; Kang SJ; Hwang S; Shin EC; Kang CY; Dong C; Chung Y
J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34083422
[TBL] [Abstract][Full Text] [Related]
18. An innovative NRF2 nano-modulator induces lung cancer ferroptosis and elicits an immunostimulatory tumor microenvironment.
Hsieh CH; Hsieh HC; Shih FS; Wang PW; Yang LX; Shieh DB; Wang YC
Theranostics; 2021; 11(14):7072-7091. PubMed ID: 34093872
[TBL] [Abstract][Full Text] [Related]
19. SUSD2 suppresses CD8
Zhao B; Gong W; Ma A; Chen J; Velegraki M; Dong H; Liu Z; Wang L; Okimoto T; Jones DM; Lei YL; Long M; Oestreich KJ; Ma Q; Xin G; Carbone DP; He K; Li Z; Wen H
Nat Immunol; 2022 Nov; 23(11):1588-1599. PubMed ID: 36266363
[TBL] [Abstract][Full Text] [Related]
20. G-CSF and G-CSFR Modulate CD4 and CD8 T Cell Responses to Promote Colon Tumor Growth and Are Potential Therapeutic Targets.
Karagiannidis I; Jerman SJ; Jacenik D; Phinney BB; Yao R; Prossnitz ER; Beswick EJ
Front Immunol; 2020; 11():1885. PubMed ID: 33042110
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
